索拉非尼联合热疗不同联合方案对肝癌HepG-2细胞增殖抑制的影响  

Inhibitory Effect of Sorafenib Combined with Hyperthermia on the Proliferation of Human Hepatocellular Carcinoma Cells Line HepG-2

作　　者：丁素银[1] 肖广显[2] 丁素静[1] 程英俊[1] DING Su-yin, XIAO Guang-xian, DING Su-jing, CHENG Ying-jun （1.Internal Oncology Department, Baoding Hengxing Hospital of Integrated Traditional and Western medicine, Baoding 071000; 2. Department of Emergency, the 252nd Hospital of PLA, Baoding 071000, China）

机构地区：[1]保定恒兴中西医结合医院肿瘤内科,河北保定071000 [2]解放军第252医院,河北保定071000

出　　处：《医学信息》2011年第15期5003-5004,共2页Journal of Medical Information

摘　　要：目的探讨索拉非尼（Sorafenib）联合热疗（hyperthermia）不同联合方案对肝癌HepG-2细胞增殖抑制的影响。方法索拉非尼及热疗单独、同时、序贯联合后以MTT法测定HepG-2细胞增殖。结果索拉非尼和热疗均对肝癌HepG-2细胞增殖抑制作用（P〈0．01），同时应用具有协同作用（P〈0．01）；索拉非尼先用组与热疗先用组相比疗效相似（P〉0．05），同时联合组高于序贯联合组（P〈0．01），联合组及序贯用药组均优于索拉非尼及热疗单用组。联合组均高于单独应用组（P〈0．01）。结论索拉非尼和热疗对肝癌HepG-2细胞均有增殖抑制作用，索拉非尼联合热疗具有协同作用。Objective To observe the inhibitory effect on the Proliferation of HepG-2 cells by the treatment of sorafenib combined with hyperthermia. Methods The Proliferation of HepG-2 cells was determined by MTT assy after administration with sorafenib alone, hyperthermia alone or sorafenib in combination with hyperthermia. Results Either sorafenib or hyperthermia had an inhibitory effect on HepG-2 cells and sorafenib combined with hyperthermia revealed a synergistic effect （P〈0.01）. The efficacy in patients receiving sequential chemotherapy with sorafenib was similar to that in patients receiving sequential chemotherapy with hyperthermia （P〉0.05）. The inhibitory effect was higher in the dual-therapy group than in the monotherapy groups （P〈0.01）. The inhibitory effect was higher in sorafenib combined with hyperthermia than the sequential chemotherapy （P〈0.01）. Conclusions Sorafenib or hyperthermia alone has an inhibitory effect on the proliferation of HepG-2 cells. Simultaneous administration with sorafenib and hyperthermia has a synergistic effect. Sequential chemotherapy is higher than the sorafenib or hyperthermia alone.

关 键 词：索拉非尼 热疗 肝癌HEPG-2细胞 增殖 

分 类 号：R382.5[医药卫生—医学寄生虫学;医药卫生—基础医学]